Peter Galettis

3.0k total citations · 1 hit paper
69 papers, 2.3k citations indexed

About

Peter Galettis is a scholar working on Oncology, Pharmacology and Molecular Biology. According to data from OpenAlex, Peter Galettis has authored 69 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 34 papers in Oncology, 21 papers in Pharmacology and 12 papers in Molecular Biology. Recurrent topics in Peter Galettis's work include Cannabis and Cannabinoid Research (17 papers), Cancer Treatment and Pharmacology (14 papers) and Colorectal Cancer Treatments and Studies (13 papers). Peter Galettis is often cited by papers focused on Cannabis and Cannabinoid Research (17 papers), Cancer Treatment and Pharmacology (14 papers) and Colorectal Cancer Treatments and Studies (13 papers). Peter Galettis collaborates with scholars based in Australia, New Zealand and United Kingdom. Peter Galettis's co-authors include Jennifer Schneider, Catherine Lucas, Mark J. McKeage, Jennifer Martin, Bruce C. Baguley, Susan J. Berners‐Price, R.J. Bowen, D Screnci, Trevor W. Hambley and Nadia Solowij and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Peter Galettis

68 papers receiving 2.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The pharmacokinetics and the pharmacodynamics of cannabinoids

2018 475 citations Catherine Lucas, Peter Galettis et al. British Journal of Clinical Pharmacology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Peter Galettis Australia	22	958	643	403	393	250	69	2.3k
Anna Maria Malfitano Italy	31	1.3k 1.4×	429 0.7×	173 0.4×	1.0k 2.6×	424 1.7×	80	3.0k
Natalie D. Eddington United States	37	574 0.6×	647 1.0×	507 1.3×	957 2.4×	347 1.4×	122	4.0k
Federica Vacondio Italy	29	656 0.7×	193 0.3×	543 1.3×	829 2.1×	369 1.5×	85	2.1k
Paul Davies United Kingdom	36	755 0.8×	223 0.3×	122 0.3×	1.7k 4.4×	636 2.5×	95	4.9k
Helena Carmo Portugal	34	657 0.7×	435 0.7×	108 0.3×	884 2.2×	769 3.1×	113	3.6k
Sabry M. Attia Saudi Arabia	45	237 0.2×	684 1.1×	310 0.8×	2.0k 5.0×	156 0.6×	267	6.0k
A. James Giannini United States	32	268 0.3×	666 1.0×	66 0.2×	622 1.6×	452 1.8×	133	2.8k
R. A. A. Maes Netherlands	32	296 0.3×	355 0.6×	77 0.2×	765 1.9×	527 2.1×	160	3.0k
Y. Nancy Wong United States	19	239 0.2×	353 0.5×	328 0.8×	657 1.7×	171 0.7×	38	2.0k
Ana Isabel Torres‐Suárez Spain	23	814 0.8×	167 0.3×	52 0.1×	367 0.9×	248 1.0×	64	1.8k

Countries citing papers authored by Peter Galettis

Since Specialization

Citations

This map shows the geographic impact of Peter Galettis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Galettis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Galettis more than expected).

Fields of papers citing papers by Peter Galettis

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter Galettis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Galettis. The network helps show where Peter Galettis may publish in the future.

Co-authorship network of co-authors of Peter Galettis

This figure shows the co-authorship network connecting the top 25 collaborators of Peter Galettis. A scholar is included among the top collaborators of Peter Galettis based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter Galettis. Peter Galettis is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Razmovski‐Naumovski, Valentina, Jennifer Martin, Richard Chye, et al.. (2025). Design Considerations for Medicinal Cannabis Clinical Trials in People Receiving Palliative Care. Journal of Pain and Symptom Management. 69(5). e395–e408. 1 indexed citations

Martin, Jennifer, et al.. (2024). Phenotype versus genotype to optimize cancer dosing in the clinical setting—focus on 5‐fluorouracil and tyrosine kinase inhibitors. Pharmacology Research & Perspectives. 12(2). e1182–e1182. 3 indexed citations

Shortt, Jake, Peter Galettis, Chan Y. Cheah, et al.. (2023). A phase 1 clinical trial of the repurposable acetyllysine mimetic, n-methyl-2-pyrrolidone (NMP), in relapsed or refractory multiple myeloma. Clinical Epigenetics. 15(1). 15–15. 3 indexed citations

Galettis, Peter, et al.. (2023). A review of psilocybin: chemistry, clinical uses and future research directions. Australian Journal of Chemistry. 76(5). 258–263. 2 indexed citations

Tong, Ziqiu, Lars Esser, Peter Galettis, et al.. (2023). Fluoropolymer Functionalization of Organ-on-Chip Platform Increases Detection Sensitivity for Cannabinoids. Biosensors. 13(8). 779–779. 1 indexed citations

Galettis, Peter, et al.. (2023). Comparison of capecitabine concentrations determined by microsampling versus plasma concentrations for therapeutic drug monitoring: a pilot study. Journal of Pharmacy and Pharmacology. 76(2). 86–92. 1 indexed citations

Galettis, Peter, et al.. (2023). Paclitaxel and Therapeutic Drug Monitoring with Microsampling in Clinical Practice. Pharmaceuticals. 17(1). 63–63. 1 indexed citations

Ellaway, Carolyn, et al.. (2022). Efficacy and safety of cannabidivarin treatment of epilepsy in girls with Rett syndrome: A phase 1 clinical trial. Epilepsia. 63(7). 1736–1747. 23 indexed citations

Jones, Graham, et al.. (2022). Mitigating analyte to stable isotope labelled internal standard cross-signal contribution in quantitative liquid chromatography-tandem mass spectrometry. SHILAP Revista de lepidopterología. 24. 57–64. 7 indexed citations

10.

Campbell, Erin J., Yvonne Bonomo, Adam Pastor, et al.. (2021). The 5‐HT_2C receptor as a therapeutic target for alcohol and methamphetamine use disorders: A pilot study in treatment‐seeking individuals. Pharmacology Research & Perspectives. 9(3). e00767–e00767. 15 indexed citations

11.

Bonomo, Yvonne, Amanda Norman, Lisa Collins, et al.. (2021). Pharmacokinetics, Safety, and Tolerability of a Medicinal Cannabis Formulation in Patients with Chronic Non-cancer Pain on Long-Term High Dose Opioid Analgesia: A Pilot Study. Pain and Therapy. 11(1). 171–189. 9 indexed citations

12.

Menz, Bradley D., Sophie L. Stocker, Nick Verougstraete, et al.. (2020). Barriers and opportunities for the clinical implementation of therapeutic drug monitoring in oncology. British Journal of Clinical Pharmacology. 87(2). 227–236. 35 indexed citations

13.

Solowij, Nadia, Samantha J. Broyd, Lisa‐Marie Greenwood, et al.. (2019). A randomised controlled trial of vaporised Δ9-tetrahydrocannabinol and cannabidiol alone and in combination in frequent and infrequent cannabis users: acute intoxication effects. European Archives of Psychiatry and Clinical Neuroscience. 269(1). 17–35. 128 indexed citations

14.

Lucas, Catherine, Peter Galettis, Nadia Solowij, et al.. (2018). Cannabinoid Disposition After Human Intraperitoneal Use: An Insight Into Intraperitoneal Pharmacokinetic Properties in Metastatic Cancer. Clinical Therapeutics. 40(9). 1442–1447. 13 indexed citations

15.

Solowij, Nadia, et al.. (2018). Second-Hand Exposure of Staff Administering Vaporised Cannabinoid Products to Patients in a Hospital Setting. Drugs in R&D. 18(1). 41–44. 9 indexed citations

16.

Luk, Peter P., Peter Galettis, & Matthew Links. (2011). ERK phosphorylation predicts synergism between gemcitabine and the epidermal growth factor receptor inhibitor AG1478. Lung Cancer. 73(3). 274–282. 7 indexed citations

17.

Galettis, Peter, et al.. (2009). Enhancement of the activity of phenoxodiol by cisplatin in prostate cancer cells. British Journal of Cancer. 100(4). 649–655. 16 indexed citations

18.

Jiang, Xuemin, et al.. (2007). Population pharmacokinetics of gemcitabine and its metabolite in patients with cancer: effect of oxaliplatin and infusion rate. British Journal of Clinical Pharmacology. 65(3). 326–333. 22 indexed citations

19.

Gan, Hui, Peter Galettis, Ian D. Davis, et al.. (2005). A phase 1 and pharmacokinetic study of gemcitabine and oxaliplatin in patients with solid tumors. Cancer Chemotherapy and Pharmacology. 58(2). 157–164. 7 indexed citations

20.

McKeage, Mark J., Susan J. Berners‐Price, Peter Galettis, et al.. (2000). Role of lipophilicity in determining cellular uptake and antitumour activity of gold phosphine complexes. Cancer Chemotherapy and Pharmacology. 46(5). 343–350. 185 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact